Inogen INC

Inogen, Inc. announced the appointment of Andy Reding as its new Chief Operating Officer, effective July 6, 2026, to enhance operational execution and support global commercial strategies.

Inogen stockholders approved an amendment to the 2023 Equity Incentive Plan, authorizing an additional 750,000 shares for issuance.

Inogen announced first quarter 2026 financial results, reporting a 3.4% year-over-year revenue increase and reiterating its full-year guidance, while also authorizing a $30 million share repurchase program.

Inogen, Inc. has appointed medical device veteran Vafa Jamali to its Board of Directors as part of a cooperation agreement with Kent Lake Partners.

Inogen appointed Baxter/Hillrom veteran Jason Richardson as CFO, added senior commercial leaders, and reaffirmed its Q1 and full-year 2026 outlook.

Inogen, Inc. announced its fourth quarter and full year 2025 financial results, showcasing significant profitability improvements and authorizing a $30 million share repurchase program.

Inogen reported a net loss of $8.3 million for Q1 2026, driven by increased operating expenses despite a 3.4% rise in total revenue.

Inogen, Inc. reported a reduced net loss for the third quarter and nine months ended September 30, 2025, driven by increased sales revenue and lower operating expenses, despite declines in rental revenue and direct-to-consumer sales.

Inogen, Inc. reported a significant reduction in net loss for Q2 2025 and the first half of the year, driven by increased sales revenue and lower operating expenses, despite declining gross margins and rental revenue.

Inogen's Q1 2025 results show increased revenue and a reduced net loss, driven by higher demand and strategic initiatives, including a collaboration with Yuwell.

Inogen's Q3 2024 results show a significant reduction in net loss and increased sales revenue, driven by strong business-to-business demand.

Inogen's second quarter results show a revenue increase driven by business-to-business sales, offset by a decrease in rental revenue and a net loss reduction.

Inogen, Inc. reported a significant reduction in net loss for fiscal year 2025, driven by increased international sales and strategic product portfolio expansion.

Inogen's 2024 10-K filing reveals a 6.4% increase in total revenue, driven by a surge in international and domestic business-to-business sales, alongside strategic shifts in management and product development.

Physio-Assist has appointed Grgoire Ramade as Chief Commercial Officer, modifying his previous role as Senior Vice-President of International Sales.

Andrew P. Reding, EVP, COO of Inogen Inc., was granted 130,000 restricted stock units on July 6, 2026, vesting over three years.

Jennifer M. Boyer, EVP of Enterprise Enablement and Chief HR Officer at Inogen Inc., sold 10,938 shares of common stock for an aggregate of $6.5959 per share under a pre-arranged 10b5-1 trading plan.

Director Mira Sahney acquired 28,081 shares of Inogen Inc. common stock through a restricted stock unit award.

Director Vafa Jamali acquired 28,081 shares of Inogen Inc. common stock through a restricted stock unit award, as disclosed in a Form 4 filing.

Glenn S. Boehnlein, a Director at Inogen Inc., acquired 28,081 shares of common stock through a restricted stock unit award.

Inogen Inc. reports that Director Heather D. Rider acquired 28,081 shares of common stock through a restricted stock unit award.

Inogen, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 5th, proposing key governance changes including the declassification of its Board of Directors.

Inogen, Inc. announces its 2025 Annual Meeting of Stockholders, urging investors to vote on key proposals including the election of directors, ratification of auditors, executive compensation, and approval of an equity incentive plan.

Inogen announces its annual stockholders meeting to be held virtually on May 14, 2025, featuring proposals including director elections, auditor ratification, executive compensation, and equity incentive plan approval.

Inogen, Inc. announces its 2024 annual meeting and details proposals for stockholder consideration, including director elections, auditor ratification, executive compensation approval, and equity incentive plan approval.

Inogen's upcoming Annual Meeting of Stockholders on June 5, 2024, will address key proposals including the election of directors, ratification of the independent auditor, executive compensation, and approval of an amended equity incentive plan.

The Vanguard Group has filed an amended Schedule 13G for Inogen Inc., reporting 0% beneficial ownership following an internal realignment.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.2% beneficial ownership stake in Inogen Inc.'s common stock as of June 30, 2025.

Camber Capital Management LP and Stephen DuBois have filed an amended Schedule 13G, reporting a passive beneficial ownership of 3.7% of Inogen Inc.'s common stock, totaling 975,000 shares.

Brown Capital Management, LLC has filed an amended Schedule 13G indicating it no longer holds beneficial ownership in Inogen, Inc., reporting 0% of the common stock.

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. and its subsidiary Yuwell (Hong Kong) Holdings Limited have disclosed a 9.9% beneficial ownership stake in U.S. medical technology company Inogen Inc.